Gamma-butyrolactone compound and pharmaceutical composition thereof
OwnerShinn-Zong Lin, Horng-Jyh Harninventors
Life of this patent
Estimating the term…
Abstract
A γ-butyrolactone compound as shown in Formula (I) and pharmaceutical composition thereof: wherein X═N, O, S, Se; and A and B are selected from substituents having the following formula: wherein R1, R2, R3, R4, and R5 are selected from a hydrogen atom, a halogen atom, a hydroxyl group, a mercapto group, an amino group, an alkoxy group, and a nitro group. The γ-butyrolactone compound and pharmaceutical composition thereof butyrolactone have inhibitory effects on hepatoma, ovarian cancer, breast cancer, lung cancer, malignant glioblastoma or colorectal carcinoma, and are cytotoxic with high specificity to inhibit Paclitaxel-resistant tumour cells at later stage of chemotherapy without any damage on normal cells.
Claims43
A γ-butyrolactone compound as shown in Formula (I):
- wherein X═N, O, S, Se;
- and A and B are selected from substituents having the following formula:
- wherein R1, R2, R3, R4, R5 are selected from a hydrogen atom, a halogen atom, a hydroxyl group, a mercapto group, an amino group, an alkoxy group, and a nitro group.
A method for preparing extracts from Bupleurum scorzonerifolium, which comprising a γ-butyrolactone compound shown in Formula (I) as an active ingredient:
- (wherein X═N, O, S, Se;
- and A and B are selected from substituents having the following formula:
- wherein R1, R2, R3, R4, R5 are selected from a hydrogen atom, a halogen atom, a hydroxyl group, a mercapto group, an amino group, an alkoxy group, and a nitro group),
- the method comprising steps of:
- extracting a lignan mixture from Bupleurum scorzonerifolium wherein the lignan mixture further comprises at least one antineoplastic component;
- and
- isolating a Bupleurum scorzonerifolium extract from the lignan mixture.
A pharmaceutical composition for treating cell proliferative disorder, which is characterized by comprising a γ-butyrolactone compound shown in Formula (I) as an active ingredient:
- wherein X═N, O, S, Se;
- and A and B are selected from substituents having the following formula:
- wherein R1, R2, R3, R4, R5 are selected from a hydrogen atom, a halogen atom, a hydroxyl group, a mercapto group, an amino group, an alkoxy group, and a nitro group.
A pharmaceutical composition for anti RNA virus, which is characterized by having a γ-butyrolactone compound shown in Formula (I) as an active ingredient:
- wherein X═N, O, S, Se;
- and A and B are selected from substituents having the following formula:
- wherein R1, R2, R3, R4, R5 are selected from a hydrogen atom, a halogen atom, a hydroxyl group, a mercapto group, an amino group, an alkoxy group, and a nitro group.
A pharmaceutical composition for treating disorders associated with abnormal telomerase activity, which is characterized by having a γ-butyrolactone compound shown in Formula (I) as an active ingredient:
- wherein X═N, O, S, Se;
- and A and B are selected from substituents having the following formula:
- wherein R1, R2, R3, R4, R5 are selected from a hydrogen atom, a halogen atom, a hydroxyl group, a mercapto group, an amino group, an alkoxy group, and a nitro group.
Dependencies are inferred from the claim text.